Benjamin Bikman notes participants lost 12 to 22% of body weight on Lilly's triple agonist, and argues the drug works through weight loss rather than the airway itself.
Recap by typeshit. Post by Benjamin Bikman on X.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
Analysts led by Yang Huang expect about 15% yearly growth, citing the large diabetes and obesity burden across the three countries.
A clip from CNN's Body Language where two doctors point to common missteps they say lead to side effects on GLP-1 drugs. The full episode is on CNN.
Loading…